CurrentNeighborhood Health Plan of Rhode IslandPolicy N/A

Short-Acting Opioid (Opioid‑Naive) Coverage Criteria

Defines coverage and authorization logic for short-acting opioid prescriptions for opioid‑naive patients, including permitted diagnoses and a 7‑day initial authorization; applies to Neighborhood Health Plan of Rhode Island members.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyShort-Acting Opioid (Opioid‑Naive) Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material change

Effective Date2018-07

Next Review Date2025-07

Key ActionLimit initial short-acting opioid authorization for opioid‑naive patients to a 7-day duration.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

7-dayinitial authorization duration

2018-07effective date

6review dates listed

Coverage Criteria for Short-Acting Opioids (Opioid‑Naive Patients)

Initial authorization criteria

Covered when ALL of the following are met

Initial short-acting opioid authorization for opioid-naive patients: 1) Confirmed diagnosis code for at least one permitted indication: pain associated with a current cancer diagnosis, pain associated with sickle cell disease, or patient in palliative or nursing home care; 2) Documentation that the patient is not opioid‑naive after consultation with the State of Rhode Island Prescription Monitoring Program and/or the prescriber; 3) Authorization limited to a 7-day duration.

No explicit exclusions are listed in this policy.

No additional coverage notes are specified in the document.

Coding and Duration

No specific codes listedmixed

No codes listed

Initial authorization duration

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyShort-Acting Opioid (Opioid‑Naive) Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material change

Effective Date2018-07

Next Review Date2025-07

Key ActionLimit initial short-acting opioid authorization for opioid‑naive patients to a 7-day duration.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

7-day authorization duration

Effective date7/2018

Review cycle next listedNext review 7/2025; last review 4/2024

Provider Actions, Documentation, and Denial Triggers

Prior Authorization

7-day initial authorization

Initial authorization for short-acting opioid for opioid‑naive patients is limited to a 7-day duration.

7-day initial authorization for opioid‑naive patients

Documentation Required

Provider actions — PDMP and prescriber confirmation

Providers must confirm opioid‑naive status by consulting the Rhode Island Prescription Drug Monitoring Program (PDMP) and/or contacting the prescriber. Document the PDMP query and the prescriber's confirmation in the medical record.

Check and document RI PDMP query
Document prescriber consultation when used to confirm opioid status

Documentation Required

Required documentation

Required medical information: a confirmed diagnosis code for at least one permitted indication and documentation that the patient is not already being treated with opioids (opioid‑naive) after consultation with the RI PDMP and/or the prescriber.

Confirmed diagnosis code for at least one permitted indication: cancer‑related pain, sickle cell disease, palliative care, or nursing home care
Documentation that the patient is opioid‑naive (PDMP query and/or prescriber confirmation)

Denial Risk

Denial triggers

Authorization may be denied if the clinical record lacks a confirmed qualifying diagnosis (cancer‑related pain, sickle cell disease, palliative care, or nursing home care) or if there is no documented PDMP query/prescriber confirmation to show the patient is opioid‑naive.

Missing qualifying diagnosis code for a permitted indication
No documentation of RI PDMP check or prescriber confirmation of opioid‑naive status

Definitions

Opioid‑naive — definition and confirmation

DefinitionOpioid‑naive: patients for whom short‑acting opioid authorization logic applies; patient must be confirmed not opioid‑naive after consultation with the State of Rhode Island Prescription Monitoring Program and/or the prescriber

Confirmation requirement — PDMPConsult the State of Rhode Island Prescription Monitoring Program to confirm opioid‑naive status or obtain information from the prescriber

Required documentationDocumentation must include a confirmed qualifying diagnosis code and evidence of PDMP and/or prescriber consultation

Conservative Treatment Requirements

Frequency Limits

Frequency limits

Frequency limit for initial fillInitial short‑acting opioid authorization is limited to a 7‑day duration (initial fill)

Post‑initial logicPolicy logic takes over after the initial fill to determine subsequent authorization

Permitted indicationsCoverage limited to patients with a confirmed diagnosis: cancer‑related pain, sickle cell disease pain, or patients in palliative or nursing home care

Imaging Requirements

Documentation Required

Document imaging that supports the qualifying diagnosis when applicable

If imaging is relevant to the presenting pain condition, document any imaging results that support the diagnosis; the policy requires confirmation of the qualifying diagnosis (cancer-related pain, sickle cell disease, or palliative/nursing home care) as part of the authorization package.

Background

This policy governs prescribing of short‑acting opioids for patients identified as opioid‑naive. It requires confirmation of a qualifying diagnosis (pain associated with a current cancer diagnosis, pain associated with sickle cell disease, or a patient in palliative or nursing home care) and documentation that the patient is not opioid‑naive after consultation with the State of Rhode Island Prescription Monitoring Program and/or the prescriber. The policy limits the initial authorization to a 7‑day duration.

Not Covered

No services or indications are listed as not covered.